


NETT-WORKINGS

NEUROLOGICAL EMERGENCIES TREATMENT TRIALS (NETT) NETWORK

MAY 2012

PARTICIPATING HUBS AND INVESTIGATORS

Emory University
David Wright, MD
 Henry Ford Health System
Christopher Lewandowski, MD
 Medical College of Wisconsin
Tom Aufderheide, MD
 New York Presbyterian Hospital
Stephan Mayer, MD
 Oregon Health & Science University
Robert Lowe, MD, MPH
 Stanford University
James V. Quinn, MD
 Temple University
Nina Gentile, MD
 University of Arizona
Kurt Denninghoff, MD



University of California, SF
J. Claude Hemphill, III, MD
 University of Kentucky
Roger Humphries, MD
 University of Cincinnati
Arthur Pancioli, MD
 University of Maryland
Barney J. Stern, MD
 University of Minnesota
Michelle Biros, MD, MS
 University of Pennsylvania
Jill Baren, MD, MBE
 University of Texas
Elizabeth Jones, MD
 Virginia Commonwealth University
Joseph P. Ornato, MD
 Wayne State University
Robert Welch, MD

CLINICAL COORDINATING CENTER (CCC)

University of Michigan
 William Barsan, MD

National Institute of Neurological Disorders and Stroke (NINDS)

Clinical Trial Group
 Robin Conwit, MD and Scott Janis, PhD

STATISTICAL & DATA MANAGEMENT CENTER (SDMC)

Medical University of South Carolina
 Yuko Palesch, PhD

Enrollment <i>as of 5/31/12 12:00 pm EDT</i>	ALIAS	ProTECT	POINT	SHINE
Arizona	5	41	9	<i>Not Active</i>
Cincinnati	30	59	36	< 5
Emory	26	52	15	< 5
Henry Ford	12	10	29	<i>Not Active</i>
Kentucky	31	16	20	< 5
Maryland	13	< 5	17	< 5
Minnesota	22	47	30	<i>Not Active</i>
NYP	32	< 5	28	< 5
Oregon	53	19	18	<i>Not Active</i>
Stanford	23	46	27	<i>Not Active</i>
Temple	29	35	22	<i>Not Active</i>
Texas	34	52	28	< 5
UCSF	24	16	19	< 5
UPenn	39	38	71	<i>Not Active</i>
VCU	11	18	11	<i>Not Active</i>
Wayne State	28	14	57	<i>Not Active</i>
Wisconsin	9	56	12	< 5
Emmes (<i>POINT</i> only)	-	-	428	-
Ancillary Sites (<i>SHINE</i> only)	-	-	-	< 5
TOTAL	421	522	877	6

*OHSU WAS AN ORIGINAL SITE IN THE ALIAS I TRIAL AND CONTINUES IN THE ALIAS II TRIAL UNDER THE SAME CONTRACTUAL ARRANGEMENT WITH THE UNIVERSITY OF MIAMI STUDY CHAIR SITE.

PLEASED TO MEET YOU...



Arthi Ramakrishnan, MS, CCRP

SHINE Site Manager

University of Michigan, Clinical Coordinating Center

Welcome Arthi Ramakrishnan, the new SHINE Site Manager! Arthi completed her Bachelor's degree in Chennai, India, and received a Master's in Clinical Research Administration from Eastern Michigan University. She is also certified as a CCRP with SoCRA.

She has been working at the University of Michigan for six years coordinating studies in bone marrow transplant, left ventricular assist devices, and hematology-oncology.

Arthi enjoys camping, hiking, and taking walks in the park with her family. She likes to travel and loves the mountains. Arthi also enjoys cooking and watching movies. However, most of her time is devoted to her five- and two-year old sons and their activities.

Erin Zaleski, MA

RAMPART Site Manager

ProTECT Site Manager

University of Michigan, Clinical Coordinating Center

Erin has been with the NETT for almost five years and has been working in research at the University of Michigan since her undergraduate studies there. Her background is in psychology, with a BA from the University of Michigan and an MA from the Michigan School of Professional Psychology. She has a five-year old son, Jack, who keeps her running and is more than half her height! In Erin's free time, she enjoys spending time with her family and friends, and loves cooking for anyone who is around.



Joy Pinkerton, BSN, RN, MS


NETT Education Coordinator

University of Michigan, Clinical Coordinating Center

Joy is a nurse with a Master's in Health Policy and Management. She has been the NETT's Education Coordinator for the past five years. Previously, Joy worked on a variety of research studies in HIV/AIDS, asthma and pregnancy outcomes.

When she's not working Joy likes to be outdoors. She is originally from Hawaii, so naturally she enjoys spending time at the beach or pool. Playing soccer is one of her favorite activities, something she shares a love for with her two children, Wil (8 y.o.) and Meg (5 y.o.). She plays on two teams, creatively named, "Victorious Secrets" and "Violet Femmes." The best part of playing is hearing Wil and Meg cheering in the stands, "Go Mommy! Get a goal!"





High-Dose Albumin Therapy For Neuroprotection In Acute Ischemic Stroke

Principal Investigator: Myron Ginsberg, MD

Reminders

- **ALIAS2 WebDCU upgrade (effective May 21, 2012):** A new version of the WebDCU™ User Manual (v10) is posted in ALIAS2 WebDCU™. Click on *Project Management* and then *Project Documents*. Please consult this new document to assist you with any data entry questions. Contact Rick Leinster leinster@musc.edu or Aaron Perlmutter perlmutt@musc.edu if you have any questions about the new database.
- **New Study Drug Kit Labels:** There are new labels on the exterior of the kit and on the blinding boxes. On each carton, there is an additional “Blue” label that does not require any action by ALIAS2 sites outside the EU. In addition, the Bottle #2 label is now bright Green and states, “Bottle #2 use second!” Finally, on each blinding box there is a new bright Yellow label that states, “Combined dose from both Bottles should NEVER exceed 750ml”.
- **Study drug dosing and the risk of overdosing:** The new study kits have two 500ml bottles in them. **Do NOT** administer more than the maximum dose of 750ml of study drug (which is 187.5 g of ALB in 750ml OR 750 ml of normal saline). Please cross-reference IV pump measurements with a visual inspection through the semi-opaque plastic on the box to estimate the volume infused to ensure that volumes are not grossly discordant. This should be done for each bottle after it is infused. There should always be approximately 250ml of study drug left in Bottle#2. The weight of the patient, (and therefore, the dose administered) is an estimate and some study drug is always lost in the IV tubing. However, large discrepancies (>50ml) between estimated weight and administered dose should be avoided.
-Samkeliso Mawocha (smawocha@umich.edu)



Platelet-Oriented Inhibition in New TIA Trial

Principal Investigator: Clay Johnston, MD

Enrollment

Enrollment continues to grow steadily as we approach the 1000 subject mark. Keep up the good work!

Overdue 90-Day Follow-up Visits

There have been a number of overdue 90-day follow-up visits. It can be difficult to reach subjects to schedule this appointment. Please continue your efforts to contact subjects and complete this visit through 150 days. In-person visits are strongly preferred, but this visit can be conducted over the phone if the subject is unable to come in for a visit. When information is collected over the phone, please complete as many forms as possible. The NIHSS is the only form that cannot be completed over the phone.

Reminders

- When uploading the Event Packet be sure to remove all PHI: name, DOB, family names, addresses, patient ID number, etc.
- The POINT ABCD2 certification no longer has an expiration date and therefore needs to be taken only one time.
- Amendment 4 will be coming to you this summer which will include an ancillary study/blood draw.

-Tess Bonham (tbonham@umich.edu)



Stroke Hyperglycemia Insulin Network Effort Trial

Principal Investigator: Karen Johnston, MD, MSc

Thank you to all of the sites for your continued commitment to SHINE. We presently have 12 sites that have been released to enroll and are up to six enrolled subjects. Congratulations to the **University of Virginia**, **University of Utah**, **Emory**, and **West Virginia University** on their first enrollments. Keep up the great work!

-Arthi Ramakrishnan (arthrama@umich.edu)

-Amy Fansler (ac7h@hscmail.mcc.virginia.edu)



Progesterone for the Treatment of Traumatic Brain Injury

ProTECT™ III Principal Investigator: David Wright, MD

Farewell

We would like to express our sincere thanks and appreciation to Harriet Nevarez, ProTECT Project Manager and Emory Hub Study Coordinator, a.k.a. "Dr. Wright's Right Hand Woman." Her hard work and dedication has not gone unnoticed. Harriet's laugh, signature accent and jovial sense of humor will be missed. And let's not forget all those entertaining biker stories! She has a way of putting a smile on your face. We wish her only the best in her new endeavor at Emory University's Office for Clinical Research. Good luck Harriet!





Important Reminder

Beginning June 1, 2012 and until further notice, please contact Dr. Wright for any non-WebDCU data management-related ProTECT issues. His email is david.wright@emory.edu, office (404) 778-1709, cell (678) 592-5704. Dr. Tamara Espinoza will be doing the SAE and daily in-patient checks.

-Erin Zaleski (ezajaros@umich.edu)

**NETT INVESTIGATOR RETREAT
JUNE 27 (EVENING) - JUNE 28 (AFTERNOON)
ARGONAUT HOTEL, SAN FRANCISCO, CA**



**RAMPART INVESTIGATOR MEETING
JUNE 28 (EVENING) - JUNE 29 (AFTERNOON)
ARGONAUT HOTEL, SAN FRANCISCO, CA**

NETT Network

Contact Us: nett-contact@umich.edu (734) 232-2142 Website: <http://nett.umich.edu>